Sr. Director, Global Commercial Strategy Oncology, Portfolio Strategy & Early Development

Company: Disability Solutions
Location: Raritan
Posted on: April 20, 2024

Job Description:

Johnson & Johnson, is recruiting for a Sr. Director, Portfolio Strategy & Early Development in our Global Commercial Strategy Organization. The position is based in Raritan, New Jersey At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at . We are Johnson & Johnson. Our mission drives us. Our patients inspire us. We collaborate with the world for the health of everyone in it. We are guided by our . Thriving on a diverse company culture, celebrating the uniqueness of our employees and committed to inclusion. Proud to be an equal opportunity employer. The Sr. Director, Global Commercial Strategy Oncology, ST3 DAS, Portfolio Strategy & Early Development reports to the Vice President, Commercial Disease Area Strategy (DAS) Leader for ST3 (Solid Tumors Targeted Therapy) and leads a team of Global Strategic Marketing Manager(s). The Sr Director is responsible for leading the portfolio strategy for our ST3 DAS, including amivantamab. The Sr. Director, Global Commercial Strategy Oncology, ST3 DAS, Portfolio Strategy & Early Development contributes to optimizing the value of our global portfolio in collaboration with key functions across the Global Commercial Strategy Organization (GCSO), Research and Development (R&D), and business regions. Key Responsibilities:

• Lead the strategic planning and management of the ST3 portfolio, aligning it with the oncology overall business objectives
• Pipeline Evaluation: Assess the potential of new oncology assets and therapies for inclusion in the ST3 portfolio, conducting rigorous due diligence and risk assessments
• Lead development and implementation of key components of the early/ late stage and portfolio commercial strategy as appropriate, including market definition, indication sequencing, value strategy, differentiation, and preliminary positioning.
• Effectively partner with R&D and serve as the "voice of the customer" on multiple cross-functional Compound Development Teams and within the DAS, to ensure the development of highly differentiated products with strong evidence-based value propositions.
• Demonstrate strong external focus by active engagement with key stakeholders including Key Opinion Leaders as well as patient advocacy groups.
• Drive innovation and explore new opportunities to enhance the ST3 portfolio's competitiveness and value
• Support the development of a robust portfolio strategy for the DAS providing commercial input for portfolio and therapeutic area strategies and business plans.
• Proactively identify potential area of opportunity and collaborate with Business Development on the evaluation of external licensing opportunities to complement internal assets to optimize the TA pipeline.
• Portfolio Optimization: Continuously evaluate and adjust the oncology portfolio to maximize market competitiveness, profitability, and long-term growth.
• Collaborate closely with Sr. Disease Directors, regional and cross-functional teams, including R&D, clinical development, regulatory affairs, and marketing, to ensure seamless execution of portfolio strategies
• Attract talent by leveraging personal and organizational network by promoting the GCSO brand.

Keywords: Disability Solutions, Plainfield , Sr. Director, Global Commercial Strategy Oncology, Portfolio Strategy & Early Development, Executive , Raritan, New Jersey